摘要
目的观察TCH方案术前新辅助化疗对HER-2阳性乳腺癌的近期疗效及毒副反应。方法 37例女性HER-2阳性乳腺癌患者给予TCH方案术前新辅助化疗,治疗3～4周期后进行疗效和毒副反应评价。结果 37例患者中CR 5例,PR 28例,NC 4例,PD 0例,有效率为89.2%。主要毒副反应:中性粒细胞减少22例(59.5%),恶心呕吐15例(40.5%),肝功能异常8例(21.6%)。结论 TCH方案用于HER-2阳性乳腺癌患者术前辅助化疗疗效较好,毒副反应可耐受。
Objective To observe the short-term efficacy and toxicities of TCH regimen neoadjuvant chemotherapy in the treatment of HER-2 positive breast cancer. Methods The 37 female patients with HER-2 positive breast cancer accepted TCH regimen neoadjuvant chemotherapy. After 3 or 4 cycles of chemotherapy, the efficacy and toxic- ities were evaluated. Results Of the 37 cases, CR were observed in the 5 cases, PR in the 28 cases, NC in the 4 cases, no PD was observed,the overall response rate was 89.2%. The major toxicities were neutropenia （22 cases, 59.5% ）, nausea and vomiting （15 cases,40.5% ） ,liver dysfunction （8 cases,21.6% ）. Conclusion TCH regi- men neoadjuvant chemotherapy is effective for HER-2 positive breast cancer,and the toxicities can be tolerated.
出处
《肿瘤基础与临床》
2012年第2期136-138,共3页
journal of basic and clinical oncology
